XIPERE Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving XIPERE Growth

1. First FDA-Approved Suprachoroidal Therapy for Uveitic Macular Edema

A major growth driver for XIPERE is its first-in-class status. In October 2021, the therapy became the first and only treatment approved in the US for delivering medication into the suprachoroidal space to treat macular edema associated with non-infectious uveitis.

This delivery route allows targeted drug placement between the sclera and choroid, enabling higher drug concentrations at the retina while potentially reducing exposure to other ocular structures.

Being the first commercial therapy using this technology gives XIPERE a significant competitive advantage and early market penetration, particularly among retinal specialists seeking alternatives to conventional intravitreal steroid injections.

2. Large Addressable Patient Population

Uveitis represents a significant cause of vision impairment worldwide. Epidemiological estimates indicate that:

• Approximately 350,000 patients in the United States suffer from uveitis.
• More than 1 million patients globally are affected.
• Roughly one-third of these patients develop uveitic macular edema (UME), the main indication for XIPERE.

Macular edema is the leading cause of vision loss in uveitis patients, making effective treatment essential for preserving vision.

The increasing incidence of autoimmune disorders and inflammatory eye diseases is expected to expand the patient pool eligible for therapies like XIPERE.

3. Strong Market Growth in the Uveitis Treatment Segment

The overall uveitis treatment market is expanding steadily due to improved diagnosis, aging populations, and advances in targeted ocular therapies.

• The US uveitis treatment market was projected to reach around USD 550 million by 2024.
• Globally, the market is expected to exceed USD 1 billion.
• Broader analyses suggest the global uveitis treatment market could grow from about USD 2.3 billion in 2023 to USD 4.5 billion by 2032.

As a differentiated therapy addressing a major complication of uveitis, XIPERE is well positioned to capture a share of this expanding ophthalmology market.

4. Targeted Drug Delivery Technology Improving Clinical Outcomes

The proprietary SCS Microinjector(R) platform developed by Clearside Biomedical enables localized delivery of corticosteroids directly to the posterior segment of the eye.

Compared with conventional intravitreal injections, this approach offers potential advantages:

• Improved drug concentration at the retina and choroid
• Reduced exposure to anterior eye structures
• Potential reduction in steroid-related complications such as cataracts or elevated intraocular pressure

The adoption of advanced drug delivery technologies in ophthalmology is a major driver for physician adoption and long-term market growth.

5. Expanding Global Regulatory Approvals and Geographic Expansion

Another key growth driver is the ongoing geographic expansion of XIPERE approvals and commercialization partnerships.

Key milestones include:

• United States FDA approval (2021)
• Commercial launch in the US by Bausch + Lomb
• Health Canada approval in 2025

This global expansion into Asia-Pacific and other international markets could significantly increase the drug's commercial reach.

XIPERE Recent Developments

• In July 2025, Clearside Biomedical, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS(R)), announced that Health Canada has granted approval for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME).

"XIPERE Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of XIPERE for approved indication like Uveitis; as well as potential indication like Diabetic macular oedema in the 7MM. A detailed picture of XIPERE's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the XIPERE for approved and potential indications. The XIPERE market report provides insights about XIPERE's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current XIPERE performance, future market assessments inclusive of the XIPERE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of XIPERE sales forecasts, along with factors driving its market.

XIPERE Drug Summary

XIPERE (triamcinolone acetonide injectable suspension) is an FDA-approved, sterile, preservative-free corticosteroid formulation (40 mg/mL) designed for suprachoroidal administration using the SCS Microinjector, targeting macular edema associated with uveitis. As a synthetic glucocorticoid, it acts primarily as a corticosteroid hormone receptor agonist, providing potent immunosuppressive and anti-inflammatory effects by inhibiting inflammatory mediators, reducing vascular permeability, and stabilizing the blood-retinal barrier to improve visual acuity and retinal thickness. The recommended dose is 4 mg (0.1 mL) via single suprachoroidal injection, offering targeted posterior segment delivery with minimized systemic exposure compared to intravitreal or periocular routes, and it has demonstrated rapid efficacy, durable response up to 6 months, and a favorable safety profile in the Phase III TANZANITE trial. The report provides XIPERE's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the XIPERE Market Report

The report provides insights into:

• A comprehensive product overview including the XIPERE MoA, description, dosage and administration, research and development activities in approved indications like Uveitis; as well as potential indication like Diabetic macular oedema.
• Elaborated details on XIPERE regulatory milestones and other development activities have been provided in XIPERE market report.
• The report also highlights XIPERE's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The XIPERE market report also covers the patents information, generic entry and impact on cost cut.
• The XIPERE market report contains current and forecasted XIPERE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The XIPERE market report also features the SWOT analysis with analyst views for XIPERE in approved and potential indications.

Methodology:

The XIPERE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XIPERE Analytical Perspective by DelveInsight

• In-depth XIPERE Market Assessment

This XIPERE sales market forecast report provides a detailed market assessment of XIPERE for approved indication like Uveitis; as well as potential indication like Diabetic macular oedema in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted XIPERE sales data uptil 2034.

• XIPERE Clinical Assessment

The XIPERE market report provides the clinical trials information of XIPERE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

XIPERE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

XIPERE Market Potential & Revenue Forecast

• Projected market size for the XIPERE and its key indications
• Estimated XIPERE sales potential (XIPERE peak sales forecasts)
• XIPERE Pricing strategies and reimbursement landscape

XIPERE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• XIPERE Market positioning compared to existing treatments
• XIPERE Strengths & weaknesses relative to competitors

XIPERE Regulatory & Commercial Milestones

• XIPERE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

XIPERE Clinical Differentiation

• XIPERE Efficacy & safety advantages over existing drugs
• XIPERE Unique selling points

XIPERE Market Report Highlights

• In the coming years, the XIPERE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The XIPERE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XIPERE's dominance.
• Other emerging products for Uveitis; as well as potential indication like Diabetic macular oedema are expected to give tough market competition to XIPERE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XIPERE in approved and potential indications.
• Analyse XIPERE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted XIPERE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of XIPERE in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of XIPERE? How strong is XIPERE's clinical and commercial performance?
• What is XIPERE's clinical trial status in each individual indications such as Uveitis; as well as potential indication like Diabetic macular oedema and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XIPERE Manufacturers?
• What are the key designations that have been granted to XIPERE for approved and potential indications? How are they going to impact XIPERE's penetration in various geographies?
• What is the current and forecasted XIPERE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of XIPERE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to XIPERE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is XIPERE? What is the duration of therapy and what are the geographical variations in cost per patient?